Business Context and Reporting Period
This Form 6-K filing is submitted by FSD Pharma Inc., a foreign private issuer, for the month of November 2023. The report was signed on November 6, 2023, by Nathan Coyle, Chief Financial Officer. The registrant's principal executive offices are located in Toronto, Ontario, Canada. The filing serves to disclose material changes via attached exhibits rather than providing a full financial statement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a cover sheet for material change reports and does not contain a financial results table.
Material Changes
The filing discloses two material change reports as exhibits:
- Exhibit 99.1: Material Change Report dated October 13, 2023.
- Exhibit 99.2: Material Change Report dated November 2, 2023.
The specific details of these changes are not summarized in the cover text provided.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or a discussion of risks and contingencies. Investors must refer to the attached exhibits for details regarding the material changes.
Investor Verification Checklist
- Review Exhibit 99.1 (October 13, 2023) and Exhibit 99.2 (November 2, 2023) to understand the specific nature of the material changes.
- Verify the company name discrepancy: The request metadata lists "Quantum Biopharma Ltd.," but the filing explicitly identifies the registrant as FSD Pharma Inc.
- Check subsequent filings for financial data, as this Form 6-K contains no numerical financial metrics.